CORNERSTONE THERAPEUTICS INC. Restricted Stock AgreementRestricted Stock Agreement • May 9th, 2013 • Cornerstone Therapeutics Inc • Pharmaceutical preparations • Delaware
Cornerstone Therapeutics Inc. (the “Company”) has selected you to receive the restricted stock award described above, which is subject to the provisions of the Company’s 2004 Stock Incentive Plan (the “Plan”), and the terms and conditions contained in this Restricted Stock Agreement (the “Agreement”). Please confirm your acceptance of this restricted stock award and of the terms and conditions of this Agreement by signing a copy of this Agreement where indicated below.
SECOND AMENDMENT TO AMENDED AND RESTATED DEVELOPMENT AND MANUFACTURING AGREEMENTDevelopment and Manufacturing Agreement • May 9th, 2013 • Cornerstone Therapeutics Inc • Pharmaceutical preparations
THIS SECOND AMENDMENT TO AMENDED AND RESTATED DEVELOPMENT AND MANUFACTURING AGREEMENT (“Second Amendment”) is made and entered into this 27th day of February, 2013 (“Second Amendment Effective Date”) by and between BAXTER HEALTHCARE CORPORATION, a Delaware corporation (“Baxter”), and CORNERSTONE THERAPEUTICS, a Delaware corporation (“Cornerstone”).
Marsha G. Prokop Baxter Healthcare Corporation Director, Contract Management 25212 W. Illinois Route 120 (WG2-3S) BioPharma Solutions Round Lake, Illinois 60073 Tel: 847.270.5250Development and Manufacturing Agreement • May 9th, 2013 • Cornerstone Therapeutics Inc • Pharmaceutical preparations
